


SB-209670

Chemical Properties

CAS No. : 157659-79-5
 Formula: C₂₉H₂₈O₉
 Molecular Weight: 520.53
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	SB-209670 is a selective endothelin receptor antagonist that inhibits the activity of ET(B) receptors in rat vascular endothelium and vascular smooth muscle.
Targets(IC50)	Endothelin Receptor
In vivo	<p>SB 209670 (3 mg kg⁻¹, i.v. bolus + 100 micrograms kg⁻¹, i.v. infusion commencing 15 min prior to LPS ; rats) significantly augmented the hypotension as well as the vascular hyporeactivity to NA caused by endotoxaemia.[5]</p> <p>SB 209670 (3 mg kg⁻¹, i.v. bolus given 15 min prior to LPS ; LPS-rats) resulted in a reduction in 6 h-survival from 71% (control) to 30% and 13%, respectively.[5]</p> <p>SB 209670 (3 mg kg⁻¹, i.v. bolus 15 min prior to LPS ; rats) significantly augmented the serum levels of creatinine, bilirubin, GPT and GOT caused by endotoxin.[5]</p> <p>SB 209670 (3 mg kg⁻¹, i.v. bolus ; rats) significantly augmented the metabolic acidosis caused by LPS.[5]</p>

Solubility Information

Solubility	DMSO: 27.5 mg/mL (52.83 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9211 mL	9.6056 mL	19.2112 mL
5 mM	0.3842 mL	1.9211 mL	3.8422 mL
10 mM	0.1921 mL	0.9606 mL	1.9211 mL
50 mM	0.0384 mL	0.1921 mL	0.3842 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Burrell KM, et al. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. *J Pharmacol Exp Ther.* 2000 ; 292(1):449-459.
- Bunting MW, et al. Differential haemodynamic effects of endothelin receptor antagonist, SB 209670, in conscious hypertensive and normotensive rats. *Eur J Pharmacol.* 1999 ; 381(1):13-21.
- Freed MI, et al. Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone. *Clin Pharmacol Ther.* 1999 ; 65(5):473-482.
- Schroeder RL, et al. PD 142893, SB 209670, and BQ 788 selectively antagonize vascular endothelial versus vascular smooth muscle ET(B)-receptor activity in the rat. *J Cardiovasc Pharmacol.* 1998 ; 32(6):935-943.
- Ruetten H, et al. Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. *Br J Pharmacol.* 1996 ; 118(1):198-204.
- Douglas SA, et al. In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670. *Br J Pharmacol.* 1995 ; 114(2):405-413.
- Gardiner SM, et al. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. *Br J Pharmacol.* 1995 ; 116(4):2237-2244.
- Douglas SA, et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. *Circ Res.* 1994 ; 75(1):190-197.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481